Practical insights on deal-making covering licensing, partnering and M&A in the pharmaceutical, biotechnology, diagnostics and medical devices sector -get acquainted with state-of-the-art concepts and practices.
How to Determine an Accurate Addressable Market Size in Life Sciences Commercial Due Diligence Market size is one of the critical elements in the life sciences commercial due diligence, new…
How to Navigate the Discount Rate Conundrum in Biotech and Pharma Valuation In the pharmaceutical and biotechnology industry (referred to collectively as biopharma), almost all valuation and investment decisions decisions…
How to Conduct Robust Commercial Due Diligence by Looking Beyond Generics in Pharma Businesses Investors need to look beyond generics in the pharmaceutical commercial due diligence (CDD) for investment in…
How to Accurately Assess the True Addressable Market in Healthcare and Life Sciences Due Diligence Determining the appropriate addressable market is often one of the critical success factors in commercial…
How to Address Terminal Value Challenges in Pharmaceutical Asset Valuation Several stakeholders who have an interest in pharmaceutical assets employ a multitude of methods to conduct valuations. Among various valuation…
A deep understanding of the key biotechnology valuation drivers is critical for those who have an interest in biotech assets and businesses- read how to conduct pharma and biotech valuation…
Key Success Factors for Effective Pharmaceutical Due Diligence and Risk Mitigation Due diligence is defined as the process by which buyers conduct the evaluation of investment opportunities. Several factors are…